Medicines safety during COVID-19

As the medical and scientific community work tirelessly to find suitable treatments for COVID-19, pharmacovigilance research is essential to understanding the safety and efficacy of treatment alternatives.

Pharmacovigilance and COVID-19 

Our work as a global community of pharmacovigilance professionals is more important than ever. As the medical and scientific community work tirelessly to find suitable treatments for COVID-19, the efforts of the WHO Programme for International Drug Monitoring and other pharmacovigilance stakeholders are vital to the success of public health initiatives across the globe. 

To collect sufficient information about the efficacy and adverse drug reactions of treatments used against COVID-19, it's crucial that all adverse events are recorded and reported as quickly as possible.

On this page, we have collected useful information and guidelines for carrying out pharmacovigilance work during COVID-19. 

The page will be updated when there is more information that we can share publicly.

How to capture adverse event reports for COVID-19 treatments

UMC provides general guidance on what and how to record important information needed for analysing adverse event reports linked to COVID-19 treatments.

Read the guidelines

How to find adverse event reports linked to COVID-19 in VigiLyze 

This guidance contains useful reminders and tips on search techniques that may be relevant to searching VigiLyze for adverse event reports on COVID-19 treatments. 

Read the guidelines

COVID-19 safety updates in VigiLyze

Only accessible to members of the WHO PIDM, VigiLyze is UMCs main communications channel for COVID-19, where we share weekly reviews of new safety data. WHO also shares the weekly reviews in its "WHO Regulatory Update".

Log in to VigiLyze

 What is our role in COVID-19?

In an article in Uppsala Reports, one of UMCs experts outlines her thoughts on what the role of the pharmacovigilance community is in the age of COVID-19.